Fennec Reconciled Depreciation vs Operating Income Analysis

FENC Stock

USD 6.15 0.14 2.23%

Fennec Pharmaceuticals financial indicator trend analysis is much more than just examining Fennec Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fennec Pharmaceuticals is a good investment. Please check the relationship between Fennec Pharmaceuticals Reconciled Depreciation and its Operating Income accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.

Reconciled Depreciation vs Operating Income

Reconciled Depreciation vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fennec Pharmaceuticals Reconciled Depreciation account and Operating Income. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Fennec Pharmaceuticals' Reconciled Depreciation and Operating Income is -0.5. Overlapping area represents the amount of variation of Reconciled Depreciation that can explain the historical movement of Operating Income in the same time period over historical financial statements of Fennec Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Fennec Pharmaceuticals' Reconciled Depreciation and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Reconciled Depreciation of Fennec Pharmaceuticals are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Reconciled Depreciation i.e., Fennec Pharmaceuticals' Reconciled Depreciation and Operating Income go up and down completely randomly.

Correlation Coefficient

-0.5

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Reconciled Depreciation

Operating Income

Operating Income is the amount of profit realized from Fennec Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Fennec Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Fennec Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fennec Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.At present, Fennec Pharmaceuticals' Enterprise Value is projected to increase significantly based on the last few years of reporting.

Fennec Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Retained Earnings Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		0.5	-0.04	0.28	0.34	-0.3	0.49	0.35	-0.19	-0.73	0.63	0.92	-0.01	0.22	0.4	0.57	0.92	0.42	0.79	-0.71	0.8	0.52	0.53	0.68	0.48	0.35
Short Long Term Debt Total	0.5		0.46	0.81	-0.59	-0.77	-0.43	0.58	0.72	-0.74	0.95	0.19	-0.06	0.08	-0.21	0.99	0.19	0.95	0.69	-0.51	0.77	0.99	0.93	0.55	0.99	0.58
Other Current Liab	-0.04	0.46		0.88	-0.6	-0.23	-0.53	0.42	0.52	-0.27	0.34	-0.23	-0.3	-0.17	-0.27	0.39	-0.23	0.46	0.06	0.29	0.14	0.42	0.4	0.2	0.53	0.42
Total Current Liabilities	0.28	0.81	0.88		-0.63	-0.54	-0.48	0.56	0.66	-0.56	0.75	0.01	-0.19	-0.05	-0.21	0.77	0.01	0.8	0.42	-0.08	0.52	0.78	0.77	0.41	0.85	0.56
Total Stockholder Equity	0.34	-0.59	-0.6	-0.63		0.6	0.97	-0.15	-0.97	0.13	-0.4	0.64	-0.02	0.08	0.63	-0.52	0.64	-0.59	0.05	-0.16	-0.04	-0.57	-0.47	-0.04	-0.62	-0.15
Other Liab	-0.3	-0.77	-0.23	-0.54	0.6		0.5	0.05	-0.71	0.3	-0.75	-0.02	-0.33	-0.1	0.27	-0.81	-0.03	-0.74	-0.33	0.2	-0.41	-0.82	-0.76	-0.07	-0.8	0.05
Net Tangible Assets	0.49	-0.43	-0.53	-0.48	0.97	0.5		-0.04	-0.9	-0.02	-0.21	0.74	-0.09	0.04	0.64	-0.35	0.74	-0.4	0.22	-0.27	0.12	-0.41	-0.28	0.08	-0.46	-0.04
Property Plant And Equipment Net	0.35	0.58	0.42	0.56	-0.15	0.05	-0.04		0.21	-0.73	0.53	0.25	-0.47	0.02	0.01	0.52	0.26	0.52	0.66	-0.52	0.68	0.51	0.49	0.67	0.53	1.0
Net Debt	-0.19	0.72	0.52	0.66	-0.97	-0.71	-0.9	0.21		-0.25	0.57	-0.52	0.0	-0.1	-0.6	0.67	-0.52	0.74	0.12	-0.01	0.21	0.71	0.64	0.12	0.74	0.21
Retained Earnings	-0.73	-0.74	-0.27	-0.56	0.13	0.3	-0.02	-0.73	-0.25		-0.74	-0.56	0.15	-0.28	-0.13	-0.75	-0.56	-0.61	-0.89	0.81	-0.93	-0.73	-0.66	-0.89	-0.71	-0.73
Accounts Payable	0.63	0.95	0.34	0.75	-0.4	-0.75	-0.21	0.53	0.57	-0.74		0.34	0.03	0.15	-0.04	0.98	0.35	0.94	0.76	-0.57	0.84	0.96	0.97	0.54	0.94	0.53
Cash	0.92	0.19	-0.23	0.01	0.64	-0.02	0.74	0.25	-0.52	-0.56	0.34		0.04	0.28	0.56	0.26	1.0	0.07	0.66	-0.63	0.64	0.21	0.21	0.51	0.16	0.25
Non Current Assets Total	-0.01	-0.06	-0.3	-0.19	-0.02	-0.33	-0.09	-0.47	0.0	0.15	0.03	0.04		0.82	0.03	0.03	0.04	-0.17	-0.09	0.01	-0.05	0.0	-0.11	-0.23	-0.04	-0.47
Non Currrent Assets Other	0.22	0.08	-0.17	-0.05	0.08	-0.1	0.04	0.02	-0.1	-0.28	0.15	0.28	0.82		0.21	0.14	0.28	-0.12	0.24	-0.32	0.27	0.1	-0.06	0.24	0.06	0.02
Other Assets	0.4	-0.21	-0.27	-0.21	0.63	0.27	0.64	0.01	-0.6	-0.13	-0.04	0.56	0.03	0.21		-0.15	0.56	-0.27	0.23	-0.25	0.17	-0.22	-0.05	0.13	-0.24	0.01
Long Term Debt	0.57	0.99	0.39	0.77	-0.52	-0.81	-0.35	0.52	0.67	-0.75	0.98	0.26	0.03	0.14	-0.15		0.27	0.93	0.73	-0.55	0.82	0.99	0.95	0.54	0.98	0.52
Cash And Short Term Investments	0.92	0.19	-0.23	0.01	0.64	-0.03	0.74	0.26	-0.52	-0.56	0.35	1.0	0.04	0.28	0.56	0.27		0.08	0.66	-0.63	0.64	0.22	0.22	0.51	0.17	0.26
Net Receivables	0.42	0.95	0.46	0.8	-0.59	-0.74	-0.4	0.52	0.74	-0.61	0.94	0.07	-0.17	-0.12	-0.27	0.93	0.08		0.61	-0.4	0.69	0.94	0.97	0.44	0.95	0.52
Common Stock Total Equity	0.79	0.69	0.06	0.42	0.05	-0.33	0.22	0.66	0.12	-0.89	0.76	0.66	-0.09	0.24	0.23	0.73	0.66	0.61		-0.88	0.96	0.7	0.68	0.74	0.66	0.66
Retained Earnings Total Equity	-0.71	-0.51	0.29	-0.08	-0.16	0.2	-0.27	-0.52	-0.01	0.81	-0.57	-0.63	0.01	-0.32	-0.25	-0.55	-0.63	-0.4	-0.88		-0.85	-0.52	-0.48	-0.74	-0.44	-0.52
Common Stock Shares Outstanding	0.8	0.77	0.14	0.52	-0.04	-0.41	0.12	0.68	0.21	-0.93	0.84	0.64	-0.05	0.27	0.17	0.82	0.64	0.69	0.96	-0.85		0.78	0.76	0.76	0.75	0.68
Non Current Liabilities Total	0.52	0.99	0.42	0.78	-0.57	-0.82	-0.41	0.51	0.71	-0.73	0.96	0.21	0.0	0.1	-0.22	0.99	0.22	0.94	0.7	-0.52	0.78		0.94	0.52	0.99	0.51
Other Current Assets	0.53	0.93	0.4	0.77	-0.47	-0.76	-0.28	0.49	0.64	-0.66	0.97	0.21	-0.11	-0.06	-0.05	0.95	0.22	0.97	0.68	-0.48	0.76	0.94		0.45	0.93	0.49
Other Stockholder Equity	0.68	0.55	0.2	0.41	-0.04	-0.07	0.08	0.67	0.12	-0.89	0.54	0.51	-0.23	0.24	0.13	0.54	0.51	0.44	0.74	-0.74	0.76	0.52	0.45		0.51	0.67
Total Liab	0.48	0.99	0.53	0.85	-0.62	-0.8	-0.46	0.53	0.74	-0.71	0.94	0.16	-0.04	0.06	-0.24	0.98	0.17	0.95	0.66	-0.44	0.75	0.99	0.93	0.51		0.53
Property Plant And Equipment Gross	0.35	0.58	0.42	0.56	-0.15	0.05	-0.04	1.0	0.21	-0.73	0.53	0.25	-0.47	0.02	0.01	0.52	0.26	0.52	0.66	-0.52	0.68	0.51	0.49	0.67	0.53

Click cells to compare fundamentals

Fennec Pharmaceuticals Account Relationship Matchups

Fennec Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	31.4M	22.4M	26.9M	26.9M	30.9M	16.1M
Other Current Liab	776K	877K	2.2M	3.8M	4.3M	4.5M
Total Current Liabilities	2.3M	1.7M	4.6M	7.6M	8.7M	9.1M
Total Stockholder Equity	29.1M	15.8M	(2.6M)	(11.6M)	(10.5M)	(9.9M)
Net Tangible Assets	11.9M	29.1M	15.8M	(2.6M)	(3.0M)	(2.8M)
Net Debt	(30.3M)	(16.1M)	1.1M	17.7M	15.9M	16.7M
Retained Earnings	(162.1M)	(179.5M)	(203.2M)	(219.2M)	(197.3M)	(187.5M)
Accounts Payable	1.6M	777K	2.4M	3.8M	4.3M	4.6M
Cash	30.3M	21.1M	23.8M	13.3M	15.3M	11.0M
Other Assets	1.1M	27K	211K	(0.3)	(0.34)	(0.33)
Cash And Short Term Investments	30.3M	21.1M	23.8M	13.3M	15.3M	11.7M
Retained Earnings Total Equity	(131.3M)	(144.0M)	(162.1M)	(179.5M)	(161.5M)	(153.5M)
Common Stock Shares Outstanding	23.7M	26.0M	26.3M	26.6M	30.6M	32.1M
Liabilities And Stockholders Equity	31.4M	22.4M	26.9M	26.9M	30.9M	16.1M
Non Current Liabilities Total	1.6M	5.0M	24.9M	30.9M	35.6M	37.4M
Other Current Assets	1.1M	253K	833K	2.6M	3.0M	3.2M
Other Stockholder Equity	49.2M	53.2M	56.8M	62.1M	71.4M	38.1M
Total Liab	2.3M	6.6M	29.5M	38.5M	44.3M	46.5M
Total Current Assets	31.4M	22.4M	26.7M	26.9M	30.9M	32.4M
Common Stock	140.7M	140.8M	142.6M	144.3M	166.0M	174.3M
Capital Surpluse	44.9M	48.3M	49.2M	53.2M	61.2M	49.4M
Net Invested Capital	29.1M	20.8M	22.3M	19.3M	17.4M	17.3M
Net Working Capital	29.1M	20.7M	22.1M	19.3M	17.4M	17.2M
Capital Stock	140.7M	140.8M	142.6M	144.3M	166.0M	143.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

When determining whether Fennec Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fennec Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fennec Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fennec Pharmaceuticals Stock:

How To Invest In Fennec

Details

Is Fennec Stock a good investment?

Details

What is Fennec Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.

You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.04)

Revenue Per Share

1.814

Quarterly Revenue Growth

0.07

Return On Assets

0.027

Return On Equity

(10.06)

The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Fennec Reconciled Depreciation vs Operating Income Analysis

Reconciled Depreciation vs Operating Income

Reconciled Depreciation vs Operating Income Correlation Analysis

Correlation Coefficient

Reconciled Depreciation

Operating Income

Fennec Pharmaceuticals fundamental ratios Correlations

Fennec Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Fennec Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Long Term Debt	+ 0.99	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.99	Long Term Debt

Net Debt	- 0.97	Total Stockholder Equity
Common Stock Shares Outstanding	- 0.93	Retained Earnings
Net Debt	- 0.9	Net Tangible Assets
Other Stockholder Equity	- 0.89	Retained Earnings
Common Stock Total Equity	- 0.89	Retained Earnings
Retained Earnings Total Equity	- 0.88	Common Stock Total Equity